hackint0sh/New-Dataset huggingface dataset:
* on quality of life. conditions: Physical Inactivity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Participants are assigned to the intervention group or the waitlist control group. The intervention group uses the ActiveWaiting App for a week, the waitlist control group starts with a control period (one week), before using the App for a week. primaryPurpose: PREVENTION masking: DOUBLE maskingDescription: Outcomes will be selected via lime survey. Allocation to the groups will be concealed. whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 140 type: ESTIMATED name: ActiveWaiting App measure: Amount of physical activity in minutes per day measure: EQ VAS / EQ-5D-5L measure: App usage - exercise session length measure: App usage - total duration per session sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: FH Campus Wien status: RECRUITING city: Vienna country: Austria name: Andrea Greisberger, MSc role: CONTACT phone: +4316066877 phoneExt: 4717 email: andrea.greisberger@fh-campuswien.ac.at lat: 48.20849 lon: 16.37208 hasResults: False
nctId: NCT06321913 id: CIBI343Y002 briefTitle: Study of IBI343 in Subjects With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma overallStatus: NOT_YET_RECRUITING date: 2024-03-15 date: 2025-12-31 date: 2025-12-31 date: 2024-03-20 date: 2024-03-20 name: Harbin Medical University class: OTHER name: Innovent Biologics (Suzhou) Co. Ltd. briefSummary: The goal of this clinical trial\] is toevaluate the safety, tolerability and efficacy of IBI343 combined with sintilimab in the treatment of subjects with advanced gastric/gastroesophageal junction adenocarcinoma. The main aim is to evaluate the efficacy and safety of IBI343 combination treatment in subjects with advanced gastric/gastroesophageal junction adenocarcinoma.The secondary aim is to evaluate other efficacy endpoints in subjects with IBI343 combination therapy for advanced gastric/gastroesophageal junction adenocarcinoma.The exploratory purpose is to evaluate the correlation between CLDN18.2 expression levels in tumor tissues and the efficacy of IBI343 combination therapy.
Participants will be asked to enroll about 3-12 patients in the safety introduction period.，and about 25 patients are planned to be enrolled in the POC phase. conditions: Advanced Gastric/Gastroesophageal Junction Adenocarcinoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 25 type: ESTIMATED name: IBI343 combined with IBI308 measure: ORR measure: AE measure: Treatment-Emergent Adverse Event (TEAE) measure: Adverse Event of Special Interest (AESI) measure: Serious Adverse Event (SAE) measure: laboratory examinations measure: physical examinations measure: vital signs measure: PFS measure: Duration of Response (DoR) measure: Disease Control Rate (DCR) measure: Time to Response (TTR) measure: Overall Survival (OS) measure: CLDN18.2 expression level sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06321900 id: 09M206 briefTitle: Personalized Risk Prediction of Sudden Cardiac Death acronym: RESPECT overallStatus: RECRUITING date: 2023-06-02 date: 2024-12-15 date: 2025-04-30 date: 2024-03-20 date: 2024-03-20 name: Istituto Auxologico Italiano class: OTHER briefSummary: Sudden cardiac death (SCD) is the final result of cardiac arrest (CA) , defined as an abrupt and unexpected loss of cardiovascular function resulting in circulatory collapse and death. Up to 50% of cardiac deaths in Europe are due to CA. The estimated mortality of CA is approximately 90%, and significant functional and/or cognitive disabilities often persist among those who survive. The advent of the implantable cardioverter-defibrillator (ICD) has revolutionized the prevention of SCD in high-risk patients with reduced left ventricular ejection fraction (LVEF\<35%). However, the algorithm recommended by current guidelines based on LVEF, considered the only parameter to identify high-risk patients, cannot stratify the population and the spectrum of risk with high accuracy. Although the risk of CA is higher among patients with LVEF\<35% and NYHA class\>1, because of the enormity of the population size at risk (i.e., with organic heart disease and LVEF\>35%), most SCD does occur in patients with LVEF\>35%. Additionally, the majority of pts who receive the ICD for primary prevention of SCD will not benefit from the device (in the Sudden Cardiac Death in Heart Failure Trial published in 2005, the rate of appropriate ICD therapy was 21% at five years), and/or will experience some side effects of it. In the Israeli registry of patients who underwent ICD (n= 1729) or cardiac resynchronization therapy (n= 1326), the 12-year cumulative incidence of adverse events was 20% for inappropriate shock, 6% for device-related infection, and 17% for lead failure.
Moreover, recent improvements in drug treatment for HF and myocardial revascularization have further reduced the incidence of SCD in pts with low LVEF. Finally, pts with advanced HF are unlikely to benefit from ICD therapy because of the high rates of non-arrhythmic deaths. Therefore, improved risk stratification approaches to guide the selection of pts for ICD implantation are needed, and only a multiparametric approach may aim to personalize the risk prediction of SCD across the broad spectrum of the phenotypes of HF patients.
The RESPECT project has been designed to personalize the risk of SCD by integrating and interpreting information highly multidisciplinary: clinical and bio-humoral, genetics and electrocardiography, conventional and advanced cardiac imaging, and data science. The investigators hypothesized that machine learning models capable of dealing with non-linearities and complex interactions among predictors, including genetic, clinical, electrocardiographic, bio-humoral, echocardiographic, cardiac magnetic resonance (CMR), and nuclear cardiology data, would have superior accuracy in predicting the occurrence of SCD compared with the currently recommended metrics of NYHA class and LVEF by two-dimensional echocardiography and that the personalized risk prediction of SCD will translate in more cost-effective use of ICDs. In addition, the investigators will use the multiparametric predictive models to develop a cloud-computing app that will allow clinicians to predict the risk of occurrence of SCD based on specific covariate profiles of individual patients. conditions: Sudden Cardiac Death Due to Cardiac Arrhythmia conditions: Cardiomyopathies conditions: Ischemic Heart Disease conditions: Cardiovascular Diseases studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 1050 type: ESTIMATED name: Personalized risk model measure: Sudden cardiac death sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Istituto Auxologico Italiano IRCCS status: RECRUITING city: Milan zip: 20145 country: Italy name: Luigi Badano, PhD role: CONTACT phone: +390261911 phoneExt: 2319 email: l.badano@auxologico.it lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06321887 id: 5155 briefTitle: EffiCacy and sAfEty of Low doSe orAl iRon for Anaemia in IBD acronym: CAESAR overallStatus: RECRUITING date: 2023-10-20 date: 2024-10-01 date: 2025-10-01 date: 2024-03-20 date: 2024-03-20 name: Liverpool University Hospitals NHS Foundation Trust class: OTHER_GOV briefSummary: Iron deficiency anaemia (IDA) is common in inflammatory bowel disease (IBD). However, although iron is commonly prescribed, the amount of elemental iron needed to achieve clinical efficacy, and the optimal method of supplementation, are under debate. This pilot study aims to investigate the efficacy and safety of low dose and standard dose oral iron preparations for the treatment of IDA in patients with IBD. conditions: Inflammatory Bowel Disease conditions: Iron Deficiency Anemia studyType: INTERVENTIONAL phases: PHASE3 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL interventionModelDescription: This is an adaptive, open label study to compare the efficacy and tolerability of 8 weeks of low dose oral iron, in the treatment of iron deficiency anaemia in patients with inflammatory bowel disease (IBD). primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: Ferrous fumarate syrup 2.5ml/70mg (22.5mg elemental iron) name: Ferrous fumarate syrup 2.5ml/70mg(45mg elemental iron) name: Ferrous fumarate syrup 2.5ml/70mg (90mg elemental iron) measure: Change in haemoglobin concentration from baseline to week 8. measure: Assessment of iron stores at baseline and week 8 measure: Assessment of faecal calprotectin at baseline and week 8 measure: Assessment of IBD severity. For ulcerative colitis this will be done using simple colitis clinical activity index (SCCAI). Values calculated at week 0 and week 8. measure: Assessment of IBD severity. For Crohn's disease (or IBD-unclassified) the Harvey Bradshaw Index (HBI) will be used. Values calculated at week 0 and week 8. measure: Assessment of quality of life using the IBD-QUK score at baseline and week 8 measure: Assessment of patient global assessment of symptom severity by visual analogue score at baseline and week 8. measure: Assessment of fatigue at baseline and week 8 using IBD-F fatigue score measure: Assessment of possible drug-related side effects: nausea, diarrhoea, mood disturbance, sleep disturbance - will all be assessed at baseline and week 8. measure: Experimental arm 1: Assessment of faecal metabolome composition at baseline and week 8 measure: Experimental arm 2: Assessment of faecal microbiota composition at baseline and week 8 sex: ALL minimumAge: 18 Years maximumAge: 79 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Liverpool University Foundation NHS Trust status: RECRUITING city: Liverpool country: United Kingdom name: S Subramanian role: CONTACT phone: 01517062000 email: RGT@liverpoolft.nhs.uk name: T Conley role: CONTACT phone: 01517062000 email: RGT@liverpoolft.nhs.uk lat: 53.41058 lon: -2.97794 hasResults: False
nctId: NCT06321874 id: EPHIRAS briefTitle: Effects of Oxygen After Abdominal Oncological Surgery acronym: EPHIRAS overallStatus: COMPLETED date: 2011-01-01 date: 2011-11-01 date: 2011-11-01 date: 2024-03-20 date: 2024-04-10 name: Jules Bordet Institute class: OTHER briefSummary: The aims of the research is to determine whether a Hyperoxic intermittent stimuli protocol can increase reticulocyte counts, signififying a rise in EPO production, in patients undergoing abdominal surgery conditions: Abdominal Cancer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomization was conducted post-surgery in a 1:1 ratio across groups: Normobaric Oxygen Paradox (NOP) group, and a control (CTR) group. The NOP group received 60% oxygen for two hours on days 1, 3, and 5 post-surgery using a venti-mask. The CTR group did not receive oxygen therapy during the post-operatory period starting from day 1. All patients could receive oxygen during the surgery and the first 24 hours post-surgery (day 0) as needed. The belonging to one group or the other was blinded to the laboratory staff. primaryPurpose: BASIC_SCIENCE masking: SINGLE maskingDescription: The belonging to one group or the other was blinded to the laboratory staff. whoMasked: CARE_PROVIDER count: 49 type: ACTUAL name: Oxygen measure: Percentage change in reticulocyte count measure: haematocrit levels mesure measure: haemoglobin levels mesure sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Khalife Maher city: Brussels zip: 1000 country: Belgium lat: 50.85045 lon: 4.34878 hasResults: False
nctId: NCT06321861 id: Caffeine_motivation briefTitle: Motivational, Affective and Performance Effects of Caffeine Supplementation overallStatus: RECRUITING date: 2024-01-19 date: 2024-05-01 date: 2024-05-01 date: 2024-03-20 date: 2024-03-20 name: Jagiellonian University class: OTHER name: The Jerzy Kukuczka Academy of Physical Education in Katowice name: University School of Physical Education, Krakow, Poland briefSummary: The main objective of the study is to evaluate the influence of caffeine intake on participants' energetic arousal, affect, motivation to achieve a training goal, satisfaction with training, and the sense of agency during training. Consequently, participants will engage in three sessions: caffeine, placebo, and no substance (in counterbalanced order). During each session, their affective and motivational states will be assessed, along with the performance of a standardized physical exercise test. The investigators hypothesize that participants who consume caffeine (caffeine condition) will exhibit higher levels of energy and motivation compared to the other two groups. Additionally, they are expected to experience greater optimism and expectancy regarding their training goals and achieve better results in the physical exercise test.
A secondary aim of the study is to examine the impact of genetic variability on motivational and affective states of participants, as well as their performance in the physical exercise test after caffeine. The investigators will assess the CYP1A2 (-163C \> A, rs762551; characterized such as "fast" (AA genotype) and "slow" caffeine metabolizers (C-carriers)) and ADORA2A (1976T \> C; rs5751876; characterized by "high" (TT genotype) or "low" sensitivity to caffeine (C-carriers)). conditions: Caffeine conditions: Affect conditions: Goals studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Each participant will take part in three similar sessions differing by the substance they receive: caffeine (intervention group), placebo, no substance. Sessions will be about one week apart. primaryPurpose: BASIC_SCIENCE masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: Caffeine name: Placebo name: No substance measure: Energetic arousal pre-test measure: Energetic arousal post-test measure: Optimism measure: Motivation measure: Determination measure: Relative outcome expectancy measure: Success probability measure: Prospective effort measure: Agency measure: Performance in the 1RM test measure: Performance in the bar velocity in the bench press test measure: Performance in the strength-endurance test measure: Performance in the countermovement jump test measure: Satisfaction with the results measure: Retrospective effort measure: Retrospective agency measure: Goal importance measure: Prospective difficulty measure: Expected performance in the 1RM test measure: Expected performance in the bar velocity in the bench press test measure: Expected performance in the strength-endurance test measure: Expected performance in the countermovement jump test measure: Retrospective difficulty measure: Energetic arousal post-training measure: Perceived effect on agency measure: Tense arousal measure: Hedonic tone sex: ALL minimumAge: 18 Years maximumAge: 30 Years stdAges: ADULT facility: The Jerzy Kukuczka Academy of Physical Education in Katowice status: RECRUITING city: Katowice country: Poland name: Aleksandra Filip-Stachnik role: CONTACT lat: 50.25841 lon: 19.02754 hasResults: False
nctId: NCT06321848 id: DUCGM2426 briefTitle: Weaning Ventilator Using Heart, Lung And Diaphragm Ultrasound overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2026-03 date: 2026-04 date: 2024-03-20 date: 2024-03-20 name: Hanoi Medical University class: OTHER briefSummary: Postextubation distress is detrimental to the prognosis of critically ill patients with successful spontaneous breathing trial. Failure to wean is known to be connected with heart, lung, and diaphragm problems. The aim of this study was to investigate how a composite model comprising diaphragm, lung, and heart ultrasonography indications could predict the weaning outcome.
Methods: Ultrasonic features of the diaphragm, heart, and lungs are going to be collected along with clinical data about the patients. Either the successful weaning group or the failed weaning group is going to comprised the patients. Multivariate logistic regression analysis is going to be used to identify the variables that may be associated with the likelihood of weaning failure. A multiindicator combination model is going to be developed to increase the predictive accuracy after the possible indicators' accuracy in foretelling the weaning outcome was assessed. conditions: Ventilator Weaning conditions: Ultrasound studyType: OBSERVATIONAL observationalModel: ECOLOGIC_OR_COMMUNITY timePerspective: CROSS_SECTIONAL count: 190 type: ESTIMATED measure: The ventilator weaning outcome measure: The hospital length of stay measure: The ICU length of stay measure: The duration of mechanical ventilation sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06321835 id: 16-10/13 briefTitle: The Effect of Different Patient Positions on Endotracheal Tube Cuff Pressure overallStatus: COMPLETED date: 2016-12-09 date: 2018-01-15 date: 2018-06-15 date: 2024-03-20 date: 2024-03-20 name: Ege University class: OTHER briefSummary: Background: The placement of a cuffed endotracheal tube for the administration of general anesthesia is a routine procedure. In the part of the intubation tube located in the trachea, there is a balloon (cuff) to prevent gase leakage, aspiration of secretions and gastric contents into the lungs. Inadequate inflation of cuff may lead to inadequate ventilation, aspiration and associated complications, while excessive inflation may cause complications in ranging from postoperative pharyngeal complaints to tracheal rupture due to increased cuff pressure. This study aimed to determine the effect of different patient positions on the endotracheal cuff pressure in patients undergoing urological procedures.
Methods: This is a prospective study conducted on 200 patients undergoing urological procedures in supine, prone, lateral flank and litotomy positions. After intubation (T0), the cuff pressure was checked with a cuff manometer and adjusted at 25 cmH2O as the baseline and continuously monitored. The cuff pressure was checked again before (T1) and after achieving the final position (T2) and then at 5 (T3), 10 (T4), 15 (T5), 30, 45, 60, 90, 120, 150, 180 minutes after the position, at the end of the procedure (T6) and before extubation (T7). At postoperative 2nd and 12th hours, the patients were interviewed for sore throat, hoarseness and cough. conditions: Endotracheal Tube Cuff Pressure conditions: Patient Positions studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 200 type: ACTUAL name: Endotracheal tube cuff pressure measurement measure: The Effect of Different Patient Positions on Endotracheal Tube Cuff Pressure in Patients Undergoing Urological Procedures: A Prospective Study measure: The Effect of Different Patient Positions on Endotracheal Tube Cuff Pressure in Patients sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06321822 id: EPIEXOME briefTitle: Genetic Diagnosis and Personalized Medicine for Patients With Epilepsy overallStatus: RECRUITING date: 2021-08-02 date: 2025-08-02 date: 2026-12-31 date: 2024-03-20 date: 2024-03-20 name: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico class: OTHER briefSummary: Background Epilepsy is a common neurological disorder. It affects 50 million people worldwide and has the highest incidence in pediatric age. According to the latest classification of the ILAE (International League against Epilepsy), epilepsies are divided into lesional (symptomatic) and non-lesional/genetic forms. Symptomatic causes of epilepsy may include scarring, tumors, strokes, and brain developmental disorders such as dysplasias. In approximately 30% of epilepsies a genetic cause of epilepsy can be hypothesized. Since the identification of the first epilepsy gene in 1995, over the next 25 years over 500 genes associated with epilepsy have been identified. The importance of many genes and many gene variants identified in many genes is not yet clear and the mutations identified in different genes require confirmation with functional studies and confirmation on larger series of patients. Furthermore, the genetic defect underlying many patients with epilepsy remains unknown to this day, despite a high level of gene sequencing effort.
Molecular studies on these genes have demonstrated how pathogenic variants on these genes determine a protein dysfunction that can cause neuronal hyperexcitability and pathological synchronization of neuronal networks leading to epileptic seizures and brain dysfunction. A notable complication in the field of epilepsy genetics is represented by the fact that the concept of a gene/a disease is valid only in a few cases, as there is a high phenotypic and genotypic heterogeneity so that a gene can present different types of epilepsy even within the same family. This means that there is a complex multigenic and multifactorial genetic substrate for which the impact of a specific genetic variant is conditioned by variants of other genes. This concept is particularly valid for the most common epileptic forms such as idiopathic generalized epilepsies.
The integration of genetic analysis with epileptological characterization in clinical practice is increasingly crucial in defining a clear molecular diagnosis in patients whose disease cause would otherwise remain unknown, and potentially allows avoiding other unnecessary diagnostic investigations. It is therefore expected that this will lead to optimizing clinical management and reducing overall costs over time. The genetic finding can constitute a useful biomarker for defining the outcome of the disease and for guiding clinical decisions such as the best choice of therapy. Despite the advantages, before starting the genetic testing process, patients and their family members should be informed about the ethical issues that may arise from genetic testing, the technical limitations, legal aspects and costs of genetic investigation.
3. Correlation of clinical and instrumental parameters (in particular EEG and neuropsychological) of epilepsy recorded on the database with etiology, outcome and response to therapy conditions: Epilepsy studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 500 type: ESTIMATED name: Whole exome sequencing (WES) measure: Identification of the genetic cause in patients with clinically probable genetic epilepsy using WES measure: Clinical and epileptological characterization of patients with epilepsy according to ILAE seizure and epilepsy classification measure: Characterization of qualitative Electroencefagraphy (EEG) features of patients with the different epilepsy types measure: Quantitative EEG (qEEG) characterization of patients with the different epilepsy types measure: Characterization of the clinical and instrumental features of patients with specific genetic etiology sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico status: RECRUITING city: Milano zip: 20122 country: Italy name: Robertino Dilena, MD role: CONTACT phone: +390255032406 email: robertino.dilena@policlinico.mi.it lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06321809 id: HUTF-FM-DABDCO-01 briefTitle: Intensive Lifestyle Interventions to Overweight and Obese Patients in Primary Care overallStatus: COMPLETED date: 2022-01-25 date: 2022-10-01 date: 2022-12-01 date: 2024-03-20 date: 2024-03-21 name: Duygu Ayhan Baser class: OTHER name: Hacettepe University briefSummary: The goal of this clinical trial is to compare in the effect of different lifestyle interventions in overweight and obese participants. The main questions it aims to answer are: